Dublin, Aug. 16, 2017 -- The "R&D Drug Pipeline Database" newsletter has been added to Research and Markets' offering.
R&D Drug Pipeline Database: 1-Year Subscription
Subscription to this proprietary R&D Drug Pipeline Database provides 24/7 online access to information about more than 21,000 project entries (files) for therapeutic drugs on the market and on investigational drug candidates in research & development.
Pre-established and free search functions allow to identify molecules according to their:
- Product category (NCE, antibodies, proteins, DNA, RNA, cells, vaccines, peptides)
- Technology (e.g. antibody-drug conjugate, bispecific antibody)
- Target (e.g. Her2, Amyloid beta, TNF, PD-1/PD-L1)
- Pipelines (selected by target, therapeutic area, company, technology)
- Sales (for marketed antibodies, peptides and proteins)
- R&D Phase (clinical phases, market, preclinical)
- Territory (countrywise)
- Therapeutic Area (e.g. infectious, oncology, gastrointestinal)
- Drug Code/Name (for individual molecules)
Each project is specified for its Target, Therapeutic Area and R&D Phase. Use of the R&D Drug Pipeline Database is intuitive. Data sets of interest can be printed and exported as reports in Excel or Word format. Projects are being updated continuously. The R&D history of each project with online references of information sources can be viewed and printed. Sales figures of major therapeutic antibodies, proteins and peptides on the market are provided.
An advanced search function allows to combine search parameters. A scroll down menu for predefined targets and technologies conveniently selects projects of interest. By clicking on column heads of the project list, projects can be arranged in ascending or descending alphabetical or numerical order, e.g. for phase or company name.
Special Focus of the Database:
- Antibodies
- Proteins
- Peptides
- Vaccines
Purchase of the subscription provides a 1-year online access to the data of the R&D Drug Pipeline Database. Credentials to access the database will be sent by e-mail within 24 hours after purchase.
Benefits from the R&D Drug Pipeline Database:
- Intuitive use
- 24/7 online access
- Designed for structured searches
- Focused on targets, product categories and R&D phases
- Ideal for competitor analysis (companies, targets, product categories)
- Cost-effective and rapid solution for benchmarking
- Identification of licensing candidates
Project listing in a tabular format:
- Drug Codes
- Target/Mechanism of Action
- Class of Compound
- Product Category
- Company
- Territory
- Therapeutic Area
- Indication
- R&D Phase
Product Categories:
- Antibody
- Cell
- DNA
- Peptide
- Protein
- RNA
- Small Molecule
- Vaccine
Therapeutic Areas:
- Cardiovascular, blood & acute care
- Dermatology
- Gastrointestinal
- Genitourinary, gynecology & renal
- Infectious & toxicology
- Metabolism & endocrine
- Neurology & psychiatry
- Oncology
- Ophthalmolgoy & otorhinolaryngology
- Orthopedics, dental, anesthesia & surgery
- Pulmonary & respiratory
- Rheumatoid & autoimmune
Examples of Predefined Targets of the Scroll Down Menu:
- Antibody-Drug Conjugates (ADC)
- Sales of Antibodies & Proteins 2015
- CAR & TCR Engineered T-Cells and NK Cells
- Adalimumab (Humira) Biosimilars
- Her2 Antibodies
- Amyloid beta-Targeted Antibodies
- CD10-Targeted Immunotherapeutics
- Immunocytokines
- Bispecific Antibodies
- Peptide Sales 2015
- PD-1 & PD-L1 Immune Checkpoint Inhibitors
- Zika Virus Vaccines
- Coagulation Factors
- Botulinum Neurotoxins
- Human Papilloma Virus (HPV) Vaccines & Therapeutics
- G-CSF & GM-CSF
- PTH-R Agonists
- Cardiometabolic Peptides
- Immune Checkpoint Modulators
Examples of Predefined Technologies of the Scroll Down Menu:
- Transgenic XenoMouse Antibodies
- T-Cell Redirecting Bispecific Antibodies
- ADC - Pyrrolobenzodiazepine (PBD)
- Fc-Fusion Proteins
- Oligo- and Polyclonal Antibodies
For more information about this newsletter visit https://www.researchandmarkets.com/research/9l5dcs/randd_drug
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Drug Discovery


Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 



